T Cell Sciences Receives U.S. Patent For Paperdot Collection System
NEEDHAM, Mass., May 18 /PRNewswire/ -- T Cell Sciences, Inc. (Nasdaq: TCEL - news) announced today that it has been granted patent number 5,747,265 from the U.S. Patent and Trademark Office covering its Paperdot collection system.
The Paperdot collection system is a simple method for collecting blood samples on filter paper and subsequently measuring the amount of a cell- associated molecule present in the samples. The patent covers the measurement of certain cell markers (including CD4 and CD8) found on leukocytes (white blood cells) in human blood samples. The Paperdot system allows samples to be collected and stored at room temperature for later testing, an advantage over other measurement systems. T Cell Sciences owns exclusive worldwide rights to the Paperdot system.
''The Paperdot system extends and enhances the patented cell lysing technology which is embodied in our TRAx(R) test kit.'' said Una S. Ryan, Ph.D., President and Chief Executive Officer of T Cell Sciences. ''It will be especially beneficial in situations where refrigerated storage of blood samples is limited. We believe that our cell lysing technology could ultimately be leveraged into several additional applications including new diagnostic assays in infectious disease and oncology. T Cell is actively seeking partners with the expertise to realize the potential of TRAx(R), including Paperdot as a technology platform, while we focus internal resources on our exciting therapeutic programs.''
T Cell Sciences, Inc. is a biopharmaceutical company creating value by using novel applications of immunology to prevent and treat cardiovascular, pulmonary and immune disorders. The Company is engaged in discovery and early clinical development of three therapeutic programs. The most advanced clinical program focuses on developing compounds that inhibit the inappropriate activation of the complement cascade in a variety of acute and chronic diseases. The Company is engaged in the discovery of T cell activation regulators for the prevention of transplant rejection and autoimmune diseases. The Company's third program targets the development of a vaccine for the management of atherosclerosis, one of the leading causes of death in the world. Additional information on T Cell Sciences can be obtained through the Company's site on the World Wide Web: tcell.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Statements contained herein that are not historical facts may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward- looking statements made by the Company. These factors include, but are not limited to: (1) The Company's ability to successfully complete development and marketing of its products, including preclinical and clinical studies; (2) the Company's ability to successfully complete product research and development including pre-clinical and clinical studies, and commercialization; (3) the Company's ability to obtain substantial additional funding; (4) the Company's ability to obtain required governmental approvals ; and (5) the Company's ability to develop and commercialize its products before its competitors.
SOURCE: T Cell Sciences, Inc.
|
